

Leprosy Drug Pipeline

	<i>Phase I</i>	<i>Phase II</i>	<i>Phase III</i>	<i>Phase IV</i>	<i>Market</i>
Rifampicin + Clofazimine + Dapsone <small>WHO; Novartis</small>					■
Rifampicin + Dapsone <small>WHO; Novartis</small>					■
Rifampicin + Ofloxacin + Minocycline <small>WHO; Novartis</small>					■
Rifampicin + Clofazimine + Dapsone 2 <small>University of Brasilia; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Brazilian Ministry of Health; Brazilian Ministry of Science and Technology; Fundacao Alfredo da Matta; Instituto de Dermatologia Dona Libania</small>				■	